博雅生命李诣书：企业走向“价值兑现”转折点

Core Viewpoint - The article discusses the strategic direction and goals of Boya Life in response to China's economic policies, particularly focusing on expanding domestic demand and optimizing supply in the biopharmaceutical industry, emphasizing the importance of innovation and technology in achieving high-quality development [1][2][3]. Group 1: Strategic Initiatives - Boya Life aims to drive industry upgrades through "hardcore innovative technology and R&D capabilities," establishing a high-barrier innovation ecosystem [2][5]. - The company is transitioning from a "workshop" model to "intelligent manufacturing" to enhance the quality and efficiency of the supply system, addressing long-standing issues in the cell preparation and storage industry [2][3]. - Boya Life's strategy for 2025 aligns with the national "expand domestic demand" strategy, focusing on activating new consumption momentum in health [2][3]. Group 2: 2026 Strategic Goals - For 2026, Boya Life's strategic goal is to extend the lifecycle of each user, transforming the concept of "storage as the endpoint" into "lifetime asset management + health services" [5][6]. - The company plans to upgrade its cell storage business from a "safe deposit box" to "life asset management" [6]. - In product innovation, Boya Life will pursue both "serious medical new technology R&D" and "consumer-level anti-aging and health intervention solutions" in parallel [6]. Group 3: Market Position and Performance - Boya Life holds over 32% of the domestic market share for placental mesenchymal stem cell storage, showcasing its strong position in the industry [2]. - The company collaborates with over 40 top-tier hospitals in China to advance nearly 20 clinical research pipelines, ensuring high-quality development standards [2]. - Boya Life emphasizes a focus on "health compounding" rather than mere growth, aiming for performance that naturally results from technological realization [6].